Siliq (Valeant Pharmaceuticals North America LLC)


Welcome to the PulseAid listing for the Siliq drug offered from Valeant Pharmaceuticals North America LLC. This Interleukin-17 Receptor A Antagonist [EPC],Interleukin 17 Receptor A Antagonists [MoA],Antibodies, Monoclonal [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Valeant Pharmaceuticals North America LLC
NON-PROPRIETARY NAME: Brodalumab
SUBSTANCE NAME: BRODALUMAB
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Interleukin-17 Receptor A Antagonist [EPC],Interleukin 17 Receptor A Antagonists [MoA],Antibodies, Monoclonal [Chemical/Ingredient]
ROUTE: SUBCUTANEOUS
DOSAGE FORM: INJECTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2017-02-15
END MARKETING DATE: 0000-00-00


Siliq HUMAN PRESCRIPTION DRUG Details:

Item DescriptionSiliq from Valeant Pharmaceuticals North America LLC
LABELER NAME: Valeant Pharmaceuticals North America LLC
DEA SCHEDULE:
ACTIVE STRENGTH: 210(mg/1)
START MARKETING DATE: 2017-02-15
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0187-0004_f5fb3c37-72ae-4dd7-bdf5-409351980ee0
PRODUCT NDC: 0187-0004
APPLICATION NUMBER: BLA761032

Other BRODALUMAB Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Valeant Pharmaceuticals North America LLCSiliq